Emergent Biosolutions
EBS
167 hedge funds and large institutions have $818M invested in Emergent Biosolutions in 2014 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 58 increasing their positions, 61 reducing their positions, and 14 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
43% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 14
30% more capital invested
Capital invested by funds: $629M → $818M (+$189M)
3% more funds holding
Funds holding: 162 → 167 (+5)
0.79% more ownership
Funds ownership: 79.65% → 80.44% (+0.79%)
5% less repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 61
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$6.6M |
| 2 |
LSV Asset Management
Chicago,
Illinois
|
+$4.96M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$3.56M |
| 4 |
Axa
Paris,
France
|
+$2.79M |
| 5 |
FMA
Fiduciary Management Associates
Chicago,
Illinois
|
+$2.79M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
-$10.4M |
| 2 |
CM
Castleark Management
Chicago,
Illinois
|
-$4.55M |
| 3 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$4.18M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$3.8M |
| 5 |
Goldman Sachs
New York
|
-$2.15M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
176
BNP Paribas Financial Markets
Paris,
France
| – | -$38.7K | -1,816 | Closed |
|
|
IPC
177
Independent Portfolio Consultants
Boca Raton,
Florida
| – | -$31.7K | -1,330 | Closed |
|
|
PTC
178
Private Trust Company
Cleveland,
Ohio
| – | -$3K | -125 | Closed |
|
|
KT
179
Kanaly Trust
Houston,
Texas
| – | -$2K | -92 | Closed |
|
|
BKA
180
Brick & Kyle Associates
Newtown,
Pennsylvania
| – | +$381 | +16 | New |
|
EBS Hedge Fund Activity: Q4 2014 in Review
167 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q4 2014, worth a combined $818M — up 30% from $629M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new EBS positions and 14 closed out — a net gain of 6 holders — while 58 added to existing stakes and 61 trimmed.
The largest buyer was Eagle Asset Management, opening a new position worth an estimated $6.6M. The largest seller was Bank of New York Mellon, cutting an estimated $10.4M.
- 167 institutional investors held Emergent Biosolutions (EBS) as of Q4 2014, up from 162 in Q3 2014.
- Funds reported $818M of Emergent Biosolutions stock for Q4 2014, up 30% quarter-over-quarter.
- 20 funds opened new Emergent Biosolutions positions in Q4 2014 and 14 closed out, a net change of +6 holders.
- The largest Emergent Biosolutions buyer in Q4 2014 was Eagle Asset Management, an estimated $6.6M added.
- The largest Emergent Biosolutions seller in Q4 2014 was Bank of New York Mellon, an estimated $10.4M sold.
Based on aggregated 13F filings for Q4 2014.